Carregant...
Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018
IMPORTANCE: The growth of cancer drug spending in the US has outpaced spending in nearly all other sectors, and an increasing proportion of the drug development pipeline is devoted to oncology. In 2018, there was a record number of drugs entering the US market. OBJECTIVE: To estimate the number of p...
Guardat en:
| Publicat a: | JAMA Intern Med |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Medical Association
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7653539/ https://ncbi.nlm.nih.gov/pubmed/33165499 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2020.5921 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|